(MedPage Today) — FDA’s outside experts weren’t sold on the trial data for brexpiprazole (Rexulti) as an adjunctive treatment for post-traumatic stress disorder (PTSD), sinking its prospects for approval in this setting.
In a 10-1 vote on Friday…
Source link : https://www.medpagetoday.com/psychiatry/anxietystress/116588
Author :
Publish date : 2025-07-18 21:50:00
Copyright for syndicated content belongs to the linked Source.
